Legal & General Group Plc Has $5.79 Million Position in Exelixis, Inc. (EXEL)

Legal & General Group Plc boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 5.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 326,613 shares of the biotechnology company’s stock after acquiring an additional 16,918 shares during the quarter. Legal & General Group Plc’s holdings in Exelixis were worth $5,788,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Exelixis by 17.1% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 23,496 shares of the biotechnology company’s stock valued at $416,000 after buying an additional 3,428 shares during the period. Meeder Asset Management Inc. lifted its holdings in shares of Exelixis by 21.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 23,504 shares of the biotechnology company’s stock valued at $416,000 after buying an additional 4,117 shares during the period. Louisiana State Employees Retirement System lifted its holdings in shares of Exelixis by 6.8% during the 3rd quarter. Louisiana State Employees Retirement System now owns 81,600 shares of the biotechnology company’s stock valued at $1,446,000 after buying an additional 5,200 shares during the period. Wedbush Securities Inc. lifted its holdings in shares of Exelixis by 14.9% during the 3rd quarter. Wedbush Securities Inc. now owns 46,101 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 5,993 shares during the period. Finally, Vident Investment Advisory LLC lifted its holdings in shares of Exelixis by 31.0% during the 2nd quarter. Vident Investment Advisory LLC now owns 25,463 shares of the biotechnology company’s stock valued at $548,000 after buying an additional 6,030 shares during the period. 77.22% of the stock is currently owned by hedge funds and other institutional investors.

In other Exelixis news, insider Patrick J. Haley sold 9,120 shares of the stock in a transaction on Wednesday, January 9th. The stock was sold at an average price of $22.18, for a total value of $202,281.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan M. Garber sold 11,250 shares of the stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $23.00, for a total value of $258,750.00. Following the completion of the sale, the director now owns 72,579 shares of the company’s stock, valued at approximately $1,669,317. The disclosure for this sale can be found here. Insiders sold a total of 336,306 shares of company stock valued at $6,401,509 in the last quarter. 4.80% of the stock is currently owned by company insiders.

Shares of EXEL stock opened at $23.76 on Friday. Exelixis, Inc. has a 52-week low of $13.42 and a 52-week high of $31.79. The company has a quick ratio of 8.54, a current ratio of 8.66 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $7.08 billion, a price-to-earnings ratio of 46.59, a price-to-earnings-growth ratio of 1.46 and a beta of 2.09.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.22. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The business had revenue of $225.40 million during the quarter, compared to analyst estimates of $174.14 million. During the same quarter in the prior year, the business posted $0.26 EPS. Exelixis’s revenue for the quarter was up 47.8% compared to the same quarter last year. Analysts expect that Exelixis, Inc. will post 1.3 EPS for the current year.

Several equities analysts have recently weighed in on EXEL shares. TheStreet raised Exelixis from a “c+” rating to a “b-” rating in a report on Monday, December 17th. Oppenheimer set a $40.00 target price on Exelixis and gave the stock a “buy” rating in a report on Thursday, November 1st. Guggenheim began coverage on Exelixis in a report on Monday, September 17th. They issued a “buy” rating on the stock. BidaskClub raised Exelixis from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, ValuEngine raised Exelixis from a “sell” rating to a “hold” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Exelixis currently has an average rating of “Buy” and an average price target of $28.38.

COPYRIGHT VIOLATION NOTICE: “Legal & General Group Plc Has $5.79 Million Position in Exelixis, Inc. (EXEL)” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2019/01/12/legal-general-group-plc-has-5-79-million-position-in-exelixis-inc-exel.html.

Exelixis Company Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: What is a Leveraged Buyout (LBO)?

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit